|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | University of Florida |
|---|---|
| Collaborators: |
Office of Rare Diseases (ORD) Rare Diseases Clinical Research Network Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
| Information provided by (Responsible Party): | University of Florida |
| ClinicalTrials.gov Identifier: | NCT00375089 |
Purpose
Prader-Willi syndrome (PWS) is a rare genetic disorder that affects about 1 in 14,000 people in the United States. As the most commonly identified genetic cause of obesity, PWS is often confused with Early-onset Morbid Obesity (EMO). Individuals with EMO show some signs of PWS, but clinically do not have PWS. The purpose of this study is to evaluate the clinical features and genetic basis of PWS and EMO, and to determine how these conditions affect a person throughout a lifetime.
| Condition |
|---|
|
Prader-Willi Syndrome Obesity |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Prader-Willi Syndrome and Early-onset Morbid Obesity Natural History Clinical Protocol |
Blood samples for both DNA and RNA
| Estimated Enrollment: | 300 |
| Study Start Date: | September 2006 |
| Estimated Study Completion Date: | July 2014 |
| Estimated Primary Completion Date: | July 2014 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
1
Individuals with Prader-Willi syndrome
|
|
2
Individuals with Early-onset Morbid Obesity
|
PWS is a complex neurobehavioral syndrome. Clinical features include obesity, increased appetite, low muscle tone, cognitive impairment, distinct behavioral features, hypogonadism, and neonatal failure-to-thrive. It is the most commonly recognized genetic cause of obesity; however, many obese children do not in fact have PWS. These individuals are therefore diagnosed with EMO, a condition that shares features with PWS. The development of new advances and strategies for treating PWS and EMO requires a thorough understanding of the conditions at both the clinical and molecular levels. One goal of this study is to collect long-term data on individuals with PWS and EMO in order to gain a better understanding of the natural progression of the conditions, from the neonatal period well into adulthood. Specific to PWS, this study will establish a genotype-phenotype correlation among the different sub-types and will evaluate the effects of growth hormone treatment on disease progression. Lastly, the study will compare PWS with EMO in terms of clinical features and genetic basis.
Participation in this natural history study will entail an initial evaluation, followed by yearly study visits until the age of 3 and then every 2 years thereafter. Each study visit will last between 3 and 4 hours, and will include a physical exam (including a DEXA scan to determine body composition), psychological testing, an interview with the study physician, and an evaluation of the participant's diet history. In addition, blood tests will be completed for genetic testing and photos will be taken to evaluate disease progression. Cognitive and behavioral assessments will also be conducted and will last between 10 and 30 minutes.
Eligibility| Ages Eligible for Study: | up to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Individuals with Prader-Willi syndrome and Early-onset Morbid Obesity
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, California | |
| University of California at Irvine | Recruiting |
| Orange, California, United States, 92868 | |
| Contact: Virginia Kimonis, MD 714-456-5791 vkimonis@uci.edu | |
| Principal Investigator: Virginia Kimonis, MD | |
| United States, Florida | |
| University of Florida | Recruiting |
| Gainesville, Florida, United States, 32610-0296 | |
| Contact: Daniel J. Driscoll, PhD, MD 352-392-4104 driscdj@peds.ufl.edu | |
| Principal Investigator: Daniel J. Driscoll, PhD, MD | |
| Principal Investigator: Jennifer Miller, MD | |
| United States, Kansas | |
| Kansas University Medical Center | Recruiting |
| Kansas City, Kansas, United States, 66160 | |
| Contact: Merlin G. Butler, MD, PhD, FFACMG 913-588-1800 mbutler4@kumc.edu | |
| Principal Investigator: Merlin G. Butler, PhD, MD | |
| United States, Tennessee | |
| Vanderbilt University Medical Center | Recruiting |
| Nashville, Tennessee, United States | |
| Contact: Elizabeth Roof, MA 615-343-3330 elizabeth.roof@vanderbilt.edu | |
| Principal Investigator: Marshall L. Summar, MD | |
| Study Chair: | Arthur Beaudet, MD | Baylor College of Medicine |
More Information
| Responsible Party: | University of Florida |
| ClinicalTrials.gov Identifier: | NCT00375089 History of Changes |
| Other Study ID Numbers: | RDCRN 5202, U54HD061222, ARP 5202 |
| Study First Received: | September 11, 2006 |
| Last Updated: | November 8, 2011 |
| Health Authority: | United States: Federal Government |
|
Early-onset Morbid Obesity |
|
Obesity Obesity, Morbid Prader-Willi Syndrome Overnutrition Nutrition Disorders Overweight Body Weight Signs and Symptoms |
Mental Retardation Neurobehavioral Manifestations Neurologic Manifestations Nervous System Diseases Abnormalities, Multiple Congenital Abnormalities Chromosome Disorders Genetic Diseases, Inborn |